Sermonix Pharma receives Chinese approval of IND application for lasofoxifene
08 Jun 2024 //
PHARMABIZ
Sermonix Shares Details of Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient
14 Sep 2022 //
GLOBENEWSWIRE
Sermonix Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant
13 Sep 2022 //
GLOBENEWSWIRE
Sermonix Pharmaceuticals Raises $40M in Series A3 Funding
27 Nov 2021 //
FINSMES
Sermonix Project With Huntsman Cancer Institute Researcher to Investigate
21 Apr 2021 //
GLOBENEWSWIRE
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in with Eli Lilly
04 Dec 2020 //
GLOBENEWSWIRE